|
Emerging Role of Antibody‑Drug Conjugates in the Management of Non‑Small Cell Lung Cancer
|
|
Thursday, December 1, 2022
5:00 PM – 6:00 PM ET |
|
|
 |
Alexander I Spira, MD, PhD
Virginia Cancer Specialists Research Program
Fairfax, Virginia |
|
|
|
|
|
 |
Helena Yu, MD
Memorial Sloan Kettering Cancer Center
New York, New York |
|
|
|
|
|
On Thursday, December 1st, Drs Alexander Spira from Virginia Cancer Specialists Research Program and Helena Yu from Memorial Sloan Kettering Cancer Center will join me to discuss the emerging role of antibody
‑drug conjugates in the management of non
‑small cell lung cancer.
This informative webcast will feature a conversational approach centered on several challenging cases from the practices of Drs Spira and Yu. During the program, this stellar faculty will discuss their preferred treatment course for each patient, including therapies received and data informing their decisions. For those patients who participated in clinical research trials evaluating the utilization of antibody
‑drug conjugates, the faculty will talk about the biologic rationale for and design of the trial in addition to the patient’s experience with that treatment.
We hope you will
join us for this event.
- Rationale for Targeting HER2 and HER3 with Antibody-Drug Conjugates (ADCs) in Non-Small Cell Lung Cancer (NSCLC)
- Other Investigational Targets for ADCs in Advanced NSCLC
|
